Metoclopramide Hydrochloride Noridem Enterprises (Metoclopramide Hydrochloride)

The drug blocks dopamine D2 receptors in the chemoreceptor trigger zone and gastrointestinal tract, antagonises 5‑HT3 receptors, and stimulates 5‑HT4 receptors. This combination speeds gastric emptying, strengthens the lower‑esophageal sphincter, and suppresses the central vomiting reflex.

The dosage of Metoclopramide Hydrochloride is determined by the prescribing clinician based on the specific indication, patient age, weight, renal function and treatment setting. Only a qualified health professional should set the regimen.

Safety data for Metoclopramide Hydrochloride in pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with other antiemetics such as ondansetron, Metoclopramide offers both dopamine antagonism and pro‑kinetic activity, making it useful for nausea associated with delayed gastric emptying. However, it carries a higher risk of extrapyramidal side effects, so the choice depends on the clinical scenario and patient tolerance.

Store Metoclopramide Hydrochloride at controlled room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

Metoclopramide Hydrochloride is supplied for parenteral use and can be given by intramuscular injection or intravenous infusion. Administration technique, rate and dilution are determined by the prescriber and should follow institutional protocols.

Serious risks include extrapyramidal reactions such as acute dystonia, tardive dyskinesia with long‑term therapy, neuroleptic malignant syndrome, and severe depression or suicidal thoughts. Prompt medical attention is required if any of these symptoms appear.

Metoclopramide Hydrochloride is contraindicated in patients with known hypersensitivity to the drug, in those with pheochromocytoma, and in individuals with a history of severe extrapyramidal reactions. Caution is also advised for patients with gastrointestinal obstruction or perforation.